NCT02537990|Unknown
MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank
MDS
Loading search results
MDS
Sponsor study identifier
observational
1,200
1 country
1
Study Start
August 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purposes of this study are: 1. To identify and quantify the health utilities and quality of life experienced by patients who have been diagnosed with MDS and what are their predictors. 2. Measure the effects of patient related factors like frailty and comorbidity on quality of life and overall survival or toxicity to therapy. 3. Assess how quality of life changes over time and what are its predictors. This will be valuable information that may guide therapy, transfusion practices, etc., as MDS is a chronic, incurable disease that is often progressive.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2005
Date type not reportedThis date has not been verified as actual or estimated.
August 19, 2015
Actual (reported)September 2, 2015
Actual (reported)February 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
February 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
quality of life
every 6 months up to 6 years
Primary care clinic, referrals from community physicians.
Odette Cancer Center
Toronto, Ontario, M4N3M5, Canada
Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, Shamy A, Leitch HA, Christou G, Banerji V, Brian L, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Delage R, Parmentier A, Thambipillai A, Siddiqui M, Westcott C, Cameron C, Mamedov A, Spin P, Tang D. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry. Leuk Lymphoma. 2022 Dec;63(13):3165-3174. doi: 10.1080/10428194.2022.2109154. Epub 2022 Sep 12.
Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016 Jul;174(1):88-101. doi: 10.1111/bjh.14033. Epub 2016 Mar 15.
Specimens of bone marrow will be collected by aspiration when bone marrows are done for clinical purposes only. BM Plasma will be stored in aliquots, Mononuclear cells (MCs) will be isolated by density gradient centrifugation of buffy coat cells. The remainder of MC collected in this way will be used for immediate extraction of DNA by standard techniques.
Rena Buckstein, MD FRCPC
Sunnybrook Health Sciences Centre
First Submitted
August 19, 2015
First Posted
September 2, 2015
Study Start
August 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2020
Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
November 16, 2016
Record last verified: 2016-11
Individual participant data can be available to other researchers for their own patients from that center but not other centers. Collective anonymized data of all registry patients is available to them however.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: